Stock Price Update, Recognitions, and Grant of Stock Options - Research Report on Cyberonics, Hill-Rom Holdings, Bio-Reference Laboratories, Avanir Pharmaceuticals, and ImmunoGen Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 21, 2013 NEW YORK, November 21, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Cyberonics Inc. (NASDAQ: CYBX), Hill-Rom Holdings, Inc. (NYSE: HRC), Bio-Reference Laboratories Inc. (NASDAQ: BRLI), Avanir Pharmaceuticals (NASDAQ: AVNR), and ImmunoGen Inc. (NASDAQ: IMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Cyberonics Inc. Research Report On November 18, 2013, Cyberonics Inc.'s (Cyberonics) stock increased by 2.83%, ending the day at $61.42 per share. Over the past three trading sessions, the Company's stock went up by 2.93%, compared to the Dow Jones Industrial Average Index, which went up by 0.98% during the same period. The Full Research Report on Cyberonics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/ad51_CYBX -- Hill-Rom Holdings, Inc. Research Report On November 18, 2013, Hill-Rom Holdings, Inc.'s (Hill-Rom Holdings) stock was up by 0.27%, closing the day at $41.39 per share. Hill-Rom Holdings' stock was up by 0.17% over the previous three day trading sessions, compared to the S&P 500 Index, which gained 0.53% within the same period. The Full Research Report on Hill-Rom Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/777e_HRC -- Bio-Reference Laboratories Inc. Research Report On November 18, 2013, Bio-Reference Laboratories Inc.'s (Bio-Reference Laboratories) stock closed at $35.93 per share, marking an increase of 2.69%. In the last three trading sessions, the Company's stock declined by 0.03%, compared to the NASDAQ composite Index, which also went down by 0.42% during the same period. The Full Research Report on Bio-Reference Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/1f59_BRLI -- Avanir Pharmaceuticals Research Report On November 8, 2013, Avanir Pharmaceuticals announced that it approved the grant of stock options to new employees to purchase a total of 202,400 shares of common stock in the aggregate, on November 5, 2013. According to the Company, the stock options were granted as inducements material to the new employees entering into employment, with the Company, as permitted under NASDAQ Listing Rule 5635(c)(4). Additionally, Avanir Pharmaceuticals stated that it has granted seven new employees an option to purchase shares of the Company's common stock with an exercise price of $4.17 per share. The Full Research Report on Avanir Pharmaceuticals - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/2ee8_AVNR -- ImmunoGen Inc. Research Report On November 17, 2013, ImmunoGen Inc. (ImmunoGen) announced that the Company has been once again recognized as one of The Boston Globe's Top Places to Work. According to the Company, the Boston Globe's 2013 Top Places to Work survey, which was conducted by WorkplaceDynamics, measured responses of employees from numerous organizations in Massachusetts, based on six key factors that contribute to employee happiness, including company direction, execution, employee connection, workload and responsibility, management and pay and benefits. Commenting on the achievement, Daniel Junius, President and CEO of ImmunoGen stated, "ImmunoGen is focused on developing and advancing meaningful new treatments for cancer. To succeed in this mission, it is essential that we hire and retain top quality people. We are extremely pleased that our supportive culture and other key aspects of working at ImmunoGen are reflected in the survey responses and that our company has again been recognized as one of The Boston Globe's Top Places to Work." The Full Research Report on ImmunoGen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/11c8_IMGN ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas; +1-310-496-8071 (North America)
Stock Price Update, Recognitions, and Grant of Stock Options - Research Report on Cyberonics, Hill-Rom Holdings, Bio-Reference
Press spacebar to pause and continue. Press esc to stop.